Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Medicine Raises $69.6 Million in PE from JPMorgan Chase

publication date: Jan 7, 2010
China Medicine Corporation signed a deal that raises $69.6 million in new capital from One Equity Partners, the private equity investment subsidiary of JPMorgan Chase & Co. It is the first investment for One Equity Partners in China. China Medicine will use the first portion of the money to complete its $21.5 million acquisition of Guangzhou LifeTech Pharma, a transaction that helps move China Medicine from a distribution company into an integrated company with its own drugs to sell. More details...

Stock Symbol: (OTCBB: CHME)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital